Evidence map›Paper›PMID 31534634›Full record

ArticleOncotarget2019

Correction: NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia.

Anne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, Jerome Rey, Gaelle Bouvier Borg, Emmanuel Gautherot, Samuel Granjeaud, Clemence Demerle, Jean-François Hamel, Adelheid Cerwenka and 9 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Anne-Sophie ChretienTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Marseille, France.
Cyril FauriatTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Marseille, France.
Florence OrlanducciImmunomonitoring Platform, Institut Paoli-Calmettes, Marseille, France.
Jerome ReyHematology Department, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Marseille, France.
Gaelle Bouvier BorgBeckman Coulter Immunotech, Marseille, France.
Emmanuel GautherotBeckman Coulter Immunotech, Marseille, France.
Samuel GranjeaudSystems Biology Platform, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Marseille, France.
Clemence DemerleTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Marseille, France.
Jean-François HamelBiostatistics and Methodology Department, CHU Angers, Angers, France.
Adelheid CerwenkaInnate Immunity Group, German Cancer Research Center, Heidelberg, Germany.
Elke Pogge von StrandmannDepartment I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
Norbert IfrahHematology Department, CHU Angers, Angers, France.
Catherine LacombeGOELAMStheque, FILO French Innovative Leukemia Organization, Cochin Hospital, APHP, Paris, France.
Pascale Cornillet-LefebvreLaboratoire d'Hématologie, Centre Hospitalier Universitaire de Reims, Reims, France.
Jacques DelaunayService d'Hématologie, Centre Catherine de Sienne, Nantes, France.
Antoine ToubertINSERM UMRS-1160, Univ Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Immunology and Histocompatibility Department, Hôpital Saint-Louis, APHP, Paris, France.
Christine ArnouletTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Marseille, France.
Norbert VeyTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Marseille, France.
Daniel OliveTeam Immunity and Cancer, Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, Marseille, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.18632/oncotarget.17747.].

Identifiers

PMID31534634
PMCPMC6739213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.